KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Adaptive Biotechnologies (ADPT) over the last 3 years, with Dec 2024 value amounting to $336.9 million.

  • Adaptive Biotechnologies' Total Non-Current Liabilities fell 14.50% to $286.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.3 million, marking a year-over-year decrease of 14.50%. This contributed to the annual value of $336.9 million for FY2024, which is N/A change from last year.
  • Per Adaptive Biotechnologies' latest filing, its Total Non-Current Liabilities stood at $336.9 million for FY2024, which was up 26.09% from $267.2 million recorded in FY2022.
  • In the past 5 years, Adaptive Biotechnologies' Total Non-Current Liabilities ranged from a high of $336.9 million in FY2024 and a low of $267.2 million during FY2022.
  • For the 2-year period, Adaptive Biotechnologies' Total Non-Current Liabilities averaged around $302.0 million, with its median value being $302.0 million (2022).